Genetic Alterations in Preinvasive Lung Synchronous Lesions
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Despite advances in treatment, lung cancer remains the leading cause of cancer mortality. This study aimed to characterise genome-wide tumorigenesis events and to understand the hypothesis of the multistep carcinogenesis of lung adenocarcinoma (LUAD) Materials and Methods We conducted multiregion whole-exome sequencing of LUAD with synchronous atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ, or minimally invasive adenocarcinoma of 19 samples from three patients to characterize genome-wide tumorigenesis events and validate the hypothesis of the multistep carcinogenesis of LUAD. We identified potential pathogenic mutations preserved in preinvasive lesions and supplemented the finding by allelic variant level from RNA sequencing. Results Overall, independent mutational profiles were observed per patient and between patients. Some shared mutations including epidermal growth factor receptor (EGFR , p.L858R) were present across synchronous lesions. Conclusion Here, we show that there are driver gene mutations in AAH, and they may exacerbate as a sequence in a histological continuum, supporting the Darwinian evolution model of cancer genome. The intertumoral and intratumoral heterogeneity of synchronous LUAD implies that multi-biomarker strategies might be necessary for appropriate treatment.
Abstract
Purpose Despite advances in treatment, lung cancer remains the leading cause of cancer mortality. This study aimed to characterise genome-wide tumorigenesis events and to understand the hypothesis of the multistep carcinogenesis of lung adenocarcinoma (LUAD) Materials and Methods We conducted multiregion whole-exome sequencing of LUAD with synchronous atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ, or minimally invasive adenocarcinoma of 19 samples from three patients to characterize genome-wide tumorigenesis events and validate the hypothesis of the multistep carcinogenesis of LUAD. We identified potential pathogenic mutations preserved in preinvasive lesions and supplemented the finding by allelic variant level from RNA sequencing. Results Overall, independent mutational profiles were observed per patient and between patients. Some shared mutations including epidermal growth factor receptor (EGFR , p.L858R) were present across synchronous lesions. Conclusion Here, we show that there are driver gene mutations in AAH, and they may exacerbate as a sequence in a histological continuum, supporting the Darwinian evolution model of cancer genome. The intertumoral and intratumoral heterogeneity of synchronous LUAD implies that multi-biomarker strategies might be necessary for appropriate treatment.
참고문헌 (32)
- Siegel RL, "Cancer statistics, 2018", CA Cancer J Clin, 68, pp.7~30 (2018)
- Pakkala S, "Personalized therapy for lung cancer : striking a moving target", JCI Insight, 3, pp.e120858~ (2018)
- 최창민, "Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014", Cancer Research and Treatment, 51(4), pp.1400~1410 (2019), 대한암학회
- Zhang J, "Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing", Science, 346, pp.256~259 (2014)
- Travis WD, "WHO classification of tumours of the lung, pleura, thymus and heart" (2015), International Agency for Research on Cancer
- Inamura K, "Clinicopathological characteristics and mutations driving development of early lung adenocarcinoma : tumor initiation and progression", Int J Mol Sci, 19, pp.1259~ (2018)
- Izumchenko E, "Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA", Nat Commun, 6, pp.8258~ (2015)
- Sivakumar S, "Genomic landscape of atypical adenomatous hyperplasia reveals divergent modes to lung adenocarcinoma", Cancer Res, 77, pp.6119~6130 (2017)
- Park E, "Targeted sequencing analysis of pulmonary adenocarcinoma with multiple synchronous ground-glass", lepidic nodules, 2018, pp.13, 1776~1783
- Noguchi M, "Stepwise progression of pulmonary adenocarcinoma : clinical and molecular implications", Cancer Metastasis Rev, 29, pp.15~21 (2010)
- Tamborero D, "Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations", Genome Med, 10, pp.25~ (2018)
- Alves JM, "Multiregional tumor trees are not phylogenies", Trends Cancer, 3, pp.546~550 (2017)
- Bailey MH, "Comprehensive characterization of cancer driver genes and mutations", Cell, 173, pp.371~385 (2018)
- Rhee JK, "Allelic imbalance of somatic mutations in cancer genomes and transcriptomes", Sci Rep, 7, pp.1653~ (2017)
- Govindan R, "Genomic landscape of non-small cell lung cancer in smokers and never-smokers", Cell, 150, pp.1121~1134 (2012)
- Cancer Genome Atlas Research Network, "Comprehensive molecular profiling of lung adenocarcinoma", Nature, 511, pp.543~550 (2014)
- Labbe C, "Prognostic and predictive effects of TP53co-mutation in patients with EGFR-mutated non-small cell lung cancer(NSCLC)", Lung Cancer, 111, pp.23~29 (2017)
- Schmid K, "EGFR", KRAS, Clin Cancer Res, pp.2009, 15[DOI]
- Alexandrov LB, "Signatures of mutational processes in human cancer", Nature, 500, pp.415~421 (2013)
- Jamal-Hanjani M, "Tracking the evolution of non-small-cell lung cancer", N Engl J Med, 376, pp.2109~2121 (2017)
- Valero V 3rd, "Emerging role of Hpo signaling and YAP in hepatocellular carcinoma", J Hepatocell Carcinoma, 2, pp.69~78 (2015)
- Zheng W, "Integrin and gene network analysis reveals that ITGA5 and ITGB1 are prognostic in non-small-cell lung cancer", Onco Targets Ther, 9, pp.2317~2327 (2016)
- Pirinen R, "Versican in nonsmall cell lung cancer : relation to hyaluronan, clinicopathologic factors, and prognosis", Hum Pathol, 36, pp.44~50 (2005)
- Ma P, "Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer", Nat Commun, 8, pp.823~ (2017)
- He XP, "The relationship between KRAS gene mutations and HLA class I antigen downregulation in the metastasis of non-small cell lung cancer", J Int Med Res, 41, pp.1473~1483 (2013)
- Blakely CM, "Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers", Nat Genet, 49, pp.1693~1704 (2017)
- Hakimi AA, "A clear picture of renal cell carcinoma", Nat Genet, 45, pp.849~850 (2013)
- Ahn JW, "Identification of somatic mutations in EGFR", KRAS, Genome Med, pp.2014, 6[DOI]
- Park IY, "Dual chromatin and cytoskeletal remodeling by SETD2", Cell, 166, pp.950~962 (2016)
- Sottoriva A, "A Big Bang model of human colorectal tumor growth", Nat Genet, 47, pp.209~216 (2015)
- Venkatesan S, "Constraints in cancer evolution", Biochem Soc Trans, 45, pp.1~13 (2017)
- Shin HT, "Prevalence and detection of low-allele-fraction variants in clinical cancer samples", Nat Commun, 8, pp.1377~ (2017)